![COVID-19 vaccine vials [PHOTO CREDIT: BioWorld]](https://i2.wp.com/media.premiumtimesng.com/wp-content/files/2020/08/COVID-19-vaccine-vials-e1599566938402.png?fit=800%2C600&ssl=1)
South Korea is expected to mass-produce commercial COVID-19 antibody-based treatment later in September.
The deputy director of the Korea Centres for Disease Control and Prevention, Kwon Jun-wook, said this on Tuesday.
The country is currently analysing the results of phase 1 clinical trial of the antibody-based treatment, which was approved by the Ministry of Food and Drug Safety on July 17, and reviewing the phase 2, Kwon added.
As for blood plasma-based treatment, the health authorities skipped phase one of clinical trials, as the therapy itself is well-known and considered to be safe.
The country will start producing the blood plasma material for the phase 2 trial on Tuesday, while the supply of the substance will be completed in mid-October, Mr Kwon noted.
In total, clinical trials for 14 coronavirus treatments and two vaccines are currently underway in South Korea.
(Sputnik/NAN)
Advertisement
